Articles tagged with Metastasis
A study led by Dr. Frank Winkler followed the steps of tumor cell formation in real-time, revealing four stages required for metastasis development. Blocking angiogenesis with Avastin can suppress emergence of brain metastases.
Researchers found that combining targeted therapies lapatinib and trastuzumab significantly extends survival in HER2-positive breast cancer patients, with a median overall survival of 60.7 weeks compared to 41.4 weeks alone.
The new guidelines offer a range of therapeutic options and provide evidence-based recommendations for treating brain metastases. The guidelines aim to improve patient outcomes by identifying best treatment practices and fostering support for ongoing research.
Researchers use live imaging to study breast cancer cell spread, finding TGFb as the control switch. Single cells break away when TGFb is active, while clumps do so when inactive, limiting spread to local lymphatic system.
Researchers analyzed CT scans of 50 surgical patients with metastatic colorectal cancer to predict overall survival. The findings showed that morphologic changes on CT images correlated with pathologic response and improved survival.
A study found that morphologic changes on CT scans after bevacizumab-containing chemotherapy can predict overall survival in patients with stage IV colorectal cancer. The changes, including tumor size reduction and unique structural alterations, were strongly correlated with pathologic response and improved survival.
Increased Mdm2 expression drives more aggressive cancer characteristics in late-stage breast cancers. Targeting Mdm2 may help prevent progression of the disease.
Researchers found that a prolonged exposure to TGF-ß1 causes cancer cells to become even more aggressive and likely to spread. A potential treatment, nutlin3, blocks the cancer-causing effects of long-term TGF-ß1 exposure, preventing metastasis and killing cancer cells.
A study from M. D. Anderson Cancer Center reveals the interaction between Wnt/Wingless and epidermal growth factor receptor (EGFR) signaling pathways promotes tumor cell invasion and metastasis through activation of beta-catenin.
Scientists have identified a gene, AEG-1, that plays a pivotal role in two processes essential for tumor development, growth, and progression to metastasis. The gene's expression is involved in oncogenic transformation and angiogenesis, critical steps for tumor progression.
Researchers at UCLA have created a device that captures cancer cells in the blood using nano-sized features, allowing for early detection and diagnosis of metastasis. The new method may be faster and cheaper than existing technologies, capturing up to 65% of cancer cells.
The Tulane Cancer Center is conducting a phase III randomized clinical trial for Alpharadin, an injectable treatment targeting radioactive substance Radium-223. Early trials suggest it may prolong survival for men with bone metastases from prostate cancer.
Radiofrequency ablation, a local hepatic treatment for liver metastases from colorectal carcinoma, can lead to unexplained liver hemorrhage. The procedure's increasing use with few selection criteria raises concerns about minimizing complications. Early intervention is crucial in managing these complications.
Researchers at Tufts University reduced breast cancer metastasis to bone by 77 percent and overall frequency of metastasis by 36 percent in a study using an experimental agent to inhibit ROCK, a protein found to be over-expressed in metastatic breast cancer.
A study at Rush University Medical Center found that advanced equipment can largely spare the hippocampus and limbic circuit from cranial radiation, minimizing memory lapses and other cognitive effects. The researchers plan to start a clinical trial to determine the new procedure's effectiveness in preventing or treating brain metastases.
Researchers identified microRNA-mediated suppression of tumor metastasis in breast cancer, highlighting three key miR-31 targets. These targets regulate metastatic colonization, a critical step in the metastasis process.
Arizona State University scientists will study cancer cells as physical objects, examining forces, mechanical properties, and electrical properties to develop new methods for arresting tumor growth and metastasis. The goal is to understand cancer's role in the biological scheme of things and its behavior as a physical object.
The center aims to understand the explosive evolution of cancer under stress using an interdisciplinary team and physics-based approach. Researchers will create microhabitats to manipulate variables and observe cell responses, informing the development of sophisticated computer models to simulate tumor growth.
The National Cancer Institute funds a new $13 million cancer research center at Cornell University, led by Harold Craighead. The center will focus on using nanobiotechnology and other physical science approaches to advance cancer research.
The first national and evidence-based guidelines for brain metastases have been released in the US, providing a framework for treating patients with brain tumors. The guidelines cover various therapeutic options, evidence-based decision-making, and demographic factors that influence clinical decisions.
Researchers identified a cellular pathway by which alcohol promotes cancer progression through the activation of EMT in colon and breast cancer cells. This mechanism may contribute to the increased risk of these cancers associated with alcohol consumption.
Researchers discovered Snail and Twist are the major inducers of EMT in HCC, associated with reduced E-cadherin function and larger tumor size. The study provides essential information for determining liver cancer prognosis and identifying potential new treatments.
ANG1005 demonstrates disease control in over 70% of patients with progressive gliomas and brain metastases, with significant reductions in tumor size observed. The drug successfully crosses the blood-brain barrier without CNS toxicity or immunogenicity.
A case of post-gastrectomy acute pancreatitis was reported in a patient with gastric carcinoma and pancreas divisum. Early detection and aggressive treatment may improve prognosis for patients with this condition. The study highlights the importance of monitoring pancreatic function after gastrectomy.
Researchers found SRS alone reduces learning and memory problems in cancer patients with one to three brain metastases. SRS plus WBRT results in twice the risk of cognitive decline, but no survival benefit.
Researchers have identified a link between the mutated FGFR4 protein and the spread of childhood cancer. Additionally, changes in iron levels are found to affect inflammation via the TLR4 pathway, while glial cells play a crucial role in stimulating red blood cell production.
Researchers found that a mutated FGFR4 protein is associated with advanced-stage rhabdomyosarcoma and poor survival rates. Targeting this protein may offer new treatment options for individuals with the disease.
Patients with brain tumors treated with WBRT plus SRS experience significant decline in learning and memory function compared to those receiving SRS alone. The study concludes that SRS alone combined with close clinical monitoring is the preferred treatment strategy for patients newly diagnosed with one to three brain metastases.
Researchers found that SPAK silencing may promote cancer progression in B-cell lymphomas by crippling genotoxic stress signaling. In contrast, macrophage migration contributes to impaired peritoneal fluid drainage and lymphatic dysfunction in the diaphragm. Additionally, urokine plasminogen activator (uPA) is instrumental in the early ...
Researchers at Case Western Reserve University School of Medicine are investigating the role of genetic susceptibility in colon cancer metastasis. By identifying specific genes and variants, they aim to develop new anti-cancer therapies and improve patient outcomes.
Researchers found that whole-brain radiotherapy did not extend lives or improve independence in patients with limited brain metastases and stable cancer. However, it slowed cancer progression by five weeks and reduced the risk of brain-related deaths.
Researchers at UCSF have identified microRNA collections that affect distinct processes critical for cancer progression. By analyzing these 'signatures', the team found a link between deregulated microRNAs and processes like hyperproliferation, angiogenesis, and metastasis.
Researchers found that primary lung cancer shifts to metastatic disease by suppressing microRNA-200, a family of small molecules that normally locks the tumor in a noninvasive state. Protecting miR-200 from blockade completely prevented metastasis in mice.
Researchers have confirmed a link between Trichomonas vaginalis and an increased risk of prostate cancer. The study found that men infected with T. vaginalis were more likely to develop extraprostatic prostate cancer and cancer that is likely to progress to bony metastases or prostate cancer-specific death.
Researchers identified Hexokinase 2 as a key player in glucose metabolism and cell survival for breast cancer patients with brain metastases. Patients with high levels of Hexokinase 2 expression in their brain metastasis had significantly lower median survival rates compared to those with lower expression.
Researchers found that Six1 protein is central to tumor development in breast cancer, linked to EMT, stem/progenitor cells, and poor prognosis. Overexpression of Six1 also enhanced ability to metastasize, indicating its role as a key player in aggressive breast cancer.
Researchers at Albert Einstein College of Medicine have identified a distinct population of macrophages that may promote metastatic cancer growth. The study suggests that targeting these cells could inhibit tumor growth and potentially reduce cancer mortality.
New commentary published in JNCI Journal of the National Cancer Institute discusses treatment options for metastatic breast cancer. The European School of Oncology Metastatic Breast Cancer Task Force recommends sequential chemotherapy with a single agent for patients without rapid progression or life-threatening metastasis.
A team of researchers at the University of Chicago has designed a computer program that uses artificial intelligence to analyze ultrasound images and predict whether a woman's breast cancer has metastasized. The pilot study, which analyzed 50 women with suspected breast cancer, found that the AI tool accurately identified 20 cases of m...
A study by Hoag Memorial Hospital Presbyterian found that patient-specific cancer vaccines derived from patients' own cells resulted in impressive long-term survival rates. The vaccine was well-tolerated, and eight patients experienced remarkable progression-free survival despite having widely metastatic disease.
Research found that smoking increases the likelihood of pancreatic ductal adenocarcinoma becoming metastatic, with osteopontin isoform OPNc playing a key role. High levels of OPNc were detected in 87% of invasive PDA lesions from smokers, correlating with nicotine exposure.
Two matrix metalloproteinase (MMP) proteins contribute to bone metastasis in advanced breast cancer by degrading extracellular matrix and stimulating osteoclast activity. This discovery supports therapeutic targeting of MMP1 and ADAMTS1, potentially mitigating bone complications in advanced metastatic breast cancers.
A study found sunitinib to be safe and well-tolerated in patients with brain metastases, poor performance status, and elderly age groups. Median progression-free and overall survival were 10.9 and 18.4 months respectively.
Researchers have identified key signals supporting long-term survival of breast cancer cells after they spread to the bone marrow. The study found that activity of a cancer-related enzyme called Src is associated with late-onset bone metastasis and promotes cell survival.
A new study led by Memorial Sloan-Kettering Cancer Center researchers identifies the genetic function that enables breast cancer cells to survive and spread in the bone marrow. The findings support the development of therapies targeting this survival capacity, which could prevent metastasis and improve patient outcomes.
Lung cancer's rapid spread is linked to a hyperactive WNT cell-signaling pathway, enabling aggressive tumor growth and poor clinical outcomes. The study identifies two genes activated by WNT that enhance invasion and reinitiation of tumor growth in other organs.
A new three-way measurement method has been developed to predict disease metastasis in prostate cancer, combining PSA doubling time, Gleason score, and interval between surgery and detectable PSA levels. This improved prediction method may help determine which patients benefit from additional therapy after surgery.
Researchers at Max Delbrück Center for Molecular Medicine have identified 115 genes associated with metastatic potential in colorectal cancer. The study found that BAMBI gene is more active in metastatic tumors, promoting metastasis formation through key signaling pathways.
A €12 million European Union-funded study led by the University of Manchester aims to tackle tumour hypoxia, a critical factor hindering effective cancer treatment. Researchers will investigate how hypoxia affects cell behavior and develop targeted therapies to improve patient outcomes.
Researchers at Whitehead Institute for Biomedical Research discovered a microRNA, miR-31, that inversely correlates with metastasis in breast cancer. Increasing miR-31 levels can help predict patient prognoses and potentially aid in the development of targeted therapies.
The presence of multiple portal vein invasion (PVI) is a significantly poor prognostic factor for hepatocellular carcinoma. Anatomical resection is recommended for patients with HCC and PVI-M, while non-anatomical resection may lead to poorer disease-free survival.
A study published in World Journal of Gastroenterology found that patients with extrahepatic disease, high carcinoembriogenic antigen levels, or multiple nodules have poorer survival rates. Despite this, advances in surgical technique and complementary treatments are increasing the number of patients benefiting from curative treatment.
A team of scientists at The University of Texas M. D. Anderson Cancer Center has identified four new targets for breast cancer treatment, including three lysophosphatidic acid receptors and the enzyme autotaxin. These targets are found to be abnormally expressed in many types of cancer and have been shown to cause cancer.
A new study has found that autoantibodies are not strongly associated with improved outcomes in melanoma patients treated with interferon. The CAPRA score was accurate in predicting bone metastasis, prostate cancer-specific mortality, and all-cause mortality at diagnosis of localized prostate cancer.
Researchers uncover molecular mechanism that enables tumor cells to attract new blood vessels continuously in the brain, even when oxygen is still abundant. The discovery could provide a basis for therapies targeting activated integrin alpha-vbeta3 to inhibit metastatic brain disease.
A national RTOG study found that prophylactic cranial irradiation (PCI) significantly decreased the incidence of brain metastases during the first year post-treatment. Patients who received PCI were two and one-half times less likely to develop brain metastasis than those who did not.
Researchers at M.D. Anderson Cancer Center found a significant increase in median overall survival from 8 to 30 months for patients with advanced disease, and a projected five-year survival rate of over 30 percent. The study attributes the improvements to better surgical interventions and new chemotherapeutic agents.
LSUHSC researchers discovered that excessive IQGAP1 production weakens cell-to-cell contacts, promoting cell migration and invasion. The study provides insights into the prolonged activated state of Cdc42, a key protein involved in cancer spread.
Researchers at the Mayo Clinic have found a triple drug combination to be an effective and tolerable option for treating metastatic HER2+ breast cancer. The regimen, which combines capecitabine, vinorelbine, and trastuzumab, has shown promising results in reducing tumor size and improving survival rates compared to traditional treatments.
Researchers found that the gene ZBP1 is silenced in metastasizing breast cancer cells due to a methyl group attachment, leading to increased cell migration and proliferation. The study suggests potential drug targets for preventing metastasis and may help predict breast tumor outcomes by identifying signs of ZBP1 silencing.